Signant and Propeller partner to improve inhaler adherence with sensor

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Catinsyrup)
(Image: Getty/Catinsyrup)

Related tags: Signant Health, Propeller Health, Asthma, Copd, eCOA, Data collection, Digital health

The two companies will combine their digital health services to offer clinical trial participants an inhaler equipped with a sensor to analyze patient adherence.

Signant Health announced that it will connect its TrialMax electronic clinical outcome assessment (eCOA) platform to Propeller Health’s inhaler sensor and linked digital health platform. The combined platform will be aimed towards patients living with asthma and chronic obstructive pulmonary disease (COPD).

According to Signant Health, the linked platforms will lead to better patient adherence to inhaled medications by allowing clients to track medication usage.

The offering is targeted at clinical trial sponsors, clinical research organizations (CROs), and academic institutions.

The ability to follow when patients are using an inhaler would allow those connected to the database to determine when symptoms are triggered, as well as how patients are following their treatment plan.

In addition, it could allow researchers to determine how patients’ use of medication relates to their response to treatment, the company stated.

In a previous interview with Outsourcing-Pharma​, Mike Nolte, CEO of Signant Health, told us how its eCOA platform is beneficial for its clients: “The more we can create enhanced visibility for customers to make good investments and decisions and help them measure the experience in the conduct of research, reversing the lens to view this from a patient perspective, the more we see an untapped area to do exciting new things.”

Bill Byrom, the company’s VP of product strategy and innovation, explained that the Propeller’s sensor allows customers to attain this visibility through ‘frictionless’ data collection.

Propeller’s website states that the sensor works with 90% of inhaled medications available on the US market.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars